真实世界证据比较维得利珠单抗与乌司奴单抗在抗肿瘤坏死因子经治的克罗恩病患者中的效果
本研究利用美国大型保险索赔数据开展回顾性队列研究,比较抗TNF经治的克罗恩病患者启动维得利珠单抗(490例)或乌司奴单抗(885例)的疗效与安全性。主要结局治疗持续超过52周无差异(校正风险比1.09,95%CI 0.95-1.25);乌司奴单抗组全因住院、非手术克罗恩病住院及感染住院风险均更低。作者主张在此难治人群中进行个体化决策,考虑患者偏好、费用及给药途径等因素。
要点
- 抗TNF经治的克罗恩病患者中,乌司奴单抗与维得利珠单抗治疗持续超过52周无显著差异。
- 乌司奴单抗组全因住院(校正HR 0.73)、非手术克罗恩病住院(校正HR 0.58)及感染住院(校正HR 0.56)风险更低。
- 作者主张对此难治人群进行个体化决策,考虑患者偏好、费用及给药途径等因素。
核心结论
- 在抗TNF经治的克罗恩病患者中,乌司奴单抗与维得利珠单抗治疗持续超过52周的比例相似,但全因住院、非手术克罗恩病住院和感染住院等次要结局 favors 乌司奴单抗。
- 作者主张在此医学难治人群中,结合患者偏好、费用及给药途径等因素进行个体化决策。
研究设计与样本
- 回顾性队列研究,使用美国大型保险公司(Anthem, Inc.)的纵向索赔数据。
- 纳入既往6个月内有抗TNF治疗并启动维得利珠单抗或乌司奴单抗的克罗恩病患者。
- 乌司奴单抗组885例,维得利珠单抗组490例。
- 采用倾向评分精细分层控制人口学、基线临床特征及既往治疗。
主要发现
- 主要结局治疗持续超过52周:校正风险比1.09(95%CI 0.95-1.25),无差异。
- 全因住院:校正风险比0.73(95%CI 0.59-0.91),乌司奴单抗组更低。
- 非手术克罗恩病住院:校正风险比0.58(95%CI 0.40-0.83),乌司奴单抗组更低。
- 感染住院:校正风险比0.56(95%CI 0.34-0.92),乌司奴单抗组更低。
关键数值与推荐
- 主要结局为治疗持续超过52周。
- 次要结局包括全因住院、克罗恩病手术住院、非手术克罗恩病住院及感染住院。
临床怎么用
- 作者主张对抗TNF经治的克罗恩病患者进行个体化决策,考虑患者偏好、费用及给药途径等因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Many patients with Crohn's disease (CD) lose response or become intolerant to antitumor necrosis factor (TNF) therapy and subsequently switch out of class. We compared the effectiveness and safety of ustekinumab to vedolizumab in a large, geographically diverse US population of TNF-experienced patients with CD. METHODS: We conducted a retrospective cohort study using longitudinal claims data from a large US insurer (Anthem, Inc.). We identified patients with CD initiating vedolizumab or ustekinumab with anti-TNF treatment in the prior 6 months. Our primary outcome was treatment persistence for >52 weeks. Secondary outcomes included (i) all-cause hospitalization, (ii) hospitalization for CD with surgery, (iii) hospitalization for CD without surgery, and (iv) hospitalization for infection. Propensity score fine stratification was used to control for demographic and baseline clinical characteristics and prior treatments. RESULTS: Among 885 new users of ustekinumab and 490 new users of vedolizumab, we observed no difference in treatment persistence (adjusted risk ratio 1.09 [95% confidence interval 0.95-1.25]). Ustekinumab was associated with a lower rate of all-cause hospitalization (adjusted hazard ratio 0.73 [0.59-0.91]), nonsurgical CD hospitalization (adjusted hazard ratio 0.58 [0.40-0.83]), and hospitalization for infection (adjusted hazard ratio 0.56 [0.34-0.92]). DISCUSSION: This real-world comparative effectiveness study of anti-TNF-experienced patients with CD initiating vedolizumab or ustekinumab showed similar treatment persistence rates beyond 52 weeks, although secondary outcomes such as all-cause hospitalizations, nonsurgical CD hospitalizations, and hospitalizations for infection favored ustekinumab initiation. We, therefore, advocate for individualized decision making in this medically refractory population, considering patient preference and other factors such as cost and route of administration.
引用
- Kappelman MD, Adimadhyam S, Hou L, et al. Real-World Evidence Comparing Vedolizumab and Ustekinumab in Antitumor Necrosis Factor-Experienced Patients With Crohn's Disease. Am J Gastroenterol. 2022. PMID: 36508681. doi:10.14309/ajg.0000000000002068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。